Hemopurifier succesful in treatment of Ebola patient-Aethlon

The Hemopurifier Blood Filter, from Aethlon, was used in the successful treatment of a critically-ill Ebola-infected patient in Frankfurt, Germany, according to data presented at the American Society of Nephrology Annual Meeting by Helmut Geiger, Chief of Nephrology at Goethe University, Frankfurt University Hospital. The patient's viral load prior to the administration of a single 6.5-hour Hemopurifier treatment was measured 400,000 virus copies per milliliter of blood (copies/ml). Post-treatment viral load was measured at 1,000 copies/ml and never again rose above that level. The treatment was well tolerated with no adverse events reported. Since the administration of Hemopurifier therapy, Frankfurt University Hospital officials have reported that Ebola virus is no longer detectable in the patient's blood and full recovery is expected. Aethlon will soon begin the first U.S. clinical Hemopurifier studies following the FDA's approval of an Investigational Device Exemption.